Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | TTR | P02766 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | TP53 | P04637 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.73 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.55 |
| ▸ | TUBB | P07437 | 4/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13259325 | 0.93 | LMNA (0.71) | MAPTLMNATTRKDM4EMEN1 | |
| SCHEMBL8206264 | 0.91 | LMNA (0.68) | MAPTLMNATTRKDM4EMEN1 | |
| SCHEMBL8206260 | 0.91 | LMNA (0.68) | MAPTLMNATTRKDM4EMEN1 | |
| Triacetylresveratrol SCHEMBL717980 | 0.89 | TTR (1.00) | MAPTLMNATTRKDM4EMEN1 | |
| Triacetylresveratrol SCHEMBL717979 | 0.89 | TTR (1.00) | MAPTLMNATTRKDM4EMEN1 | |
| SCHEMBL715254 | 0.87 | LMNA (0.81) | MAPTLMNATTRKDM4EMEN1 | |
| SCHEMBL715253 | 0.87 | LMNA (0.81) | MAPTLMNATTRKDM4EMEN1 | |
| SCHEMBL13259327 | 0.87 | LMNA (0.81) | MAPTLMNATTRKDM4EMEN1 | |
| SCHEMBL1810217 | 0.86 | KDM4E (0.81) | MAPTLMNATTRKDM4EMEN1 | |
| SCHEMBL6847961 | 0.86 | KDM4E (0.81) | MAPTLMNATTRKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | UNIVERSITY OF MIAMI (US) | 2024-07-09 | — | — | US | disclosed |
| US-20180221303-A1 | PERITONEAL THERAPEUTIC FLUID | OPTERION HEALTH AG (CH) | 2018-08-09 | — | — | US | disclosed |
| US-20180214387-A1 | AQUEOUS SOLUTION COMPRISING A POLYPHENOL | OPTERION HEALTH AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20160288090-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-10-06 | — | — | US | disclosed |
| US-8912234-B2 | Composition containing resveratrol and/or derivatives thereof and plant oil, process for producing said composition, nutraceutical and/or pharmaceutical product, and method for enhancing the potential of resveratrol | UNIAO Brasileria de Educacao e Assistencia—Mantenedora da PUCRS (BR) | 2014-12-16 | — | — | US | disclosed |
| US-20130040920-A1 | COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL | UNIAO Brasileira de Educacao e Assistencia- Matenedora da PUCRS (BR) | 2013-02-14 | — | — | US | disclosed |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040920-A1 | COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL | GPR119, MAVS, SIRT1 | MAPT 1683/4885LMNA 1562/4885TTR 1952/4885 |
| US-20160288090-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | MAPT 3368/4885LMNA 3479/4885TTR 4880/4885 |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | MAPT 3368/4885LMNA 3479/4885TTR 4880/4885 |
| US-20180214387-A1 | AQUEOUS SOLUTION COMPRISING A POLYPHENOL | SORD, AQP1, SI | MAPT 396/4885LMNA 2253/4885TTR 220/4885 |
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | GAA, MAN2B1, IDUA | MAPT 4009/4885LMNA 567/4885TTR 866/4885 |
| US-20180221303-A1 | PERITONEAL THERAPEUTIC FLUID | FABP6, ALB, FABP2 | MAPT 1954/4885LMNA 4496/4885TTR 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.